Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 9/16/14  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Shailesh D. Siroya

Wrong Shailesh D. Siroya?
 
Background

Employment History

15 Total References
Web References
Welcome to :: Bal Pharma :: - Contact Us
www.balpharma.com, 25 Sept 2007 [cached]
Mr.Shailesh D. SiroyaManaging Director : shailesh@balpharma.comPh.(Direct) - +91 80 41379555/556FAX(Direct)- +91 80 22354058
Mr. Shailesh ...
www.ipc-2011.com, 14 July 2013 [cached]
Mr. Shailesh Siroya Managing Director, BAL Pharma Ltd.,
Commenting at the launch, Mr ...
www.biospectrumasia.com, 31 July 2008 [cached]
Commenting at the launch, Mr Shailesh Siroya, Managing Director, Bal Pharma, said, "For long, Bangalore has been known as the IT capital of India and somehow everything else has been shadowed.
Bal Pharma bets big on Japan Pharma Market - Pharma & Bio Ingredients
www.pharmabioingredients.com, 13 June 2008 [cached]
This provides a big opportunity for India's generic players, as Japan believes in the Indian quality," said Shailesh Siroya, managing director, Bal Pharma.
Of the $60 billion Japanese pharmaceutical market, generic drugs constitute only 5-7 per cent at present, whereas they account for about 60 per cent of all prescription drug sales in the West. Now that the Japanese government has started promoting the more affordable generic drugs, especially for those receiving free medical care under the welfare schemes, it is estimated that generics will account for about 20 per cent of its pharmaceutical market in a span of two years.
Siroya said Ebastine's global sales are estimated to be $350 million, of which Japan accounts for around $100 million. Ebastine is coming off patent by next year, and "this is where we stand to gain", he added.
...
With Rs 76 crore turnover last fiscal, Bal Pharma aims to be a Rs 100-crore firm in a couple of years, mainly through growth in the international markets. and branded formulations, Siroya said.
ECRON ACUNOVA
www.ecronacunova.com, 1 Jan 2006 [cached]
3 crore in a new research facility at Bommasandra, near Bangalore with an intention for contract research jobs that is expected to be a potential revenue generator. said Shailesh Siroya, managing director, Bal Pharma.
Other People with the name "Siroya":
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304